Most importantly, we could speculate that targeting MAGE-C1/CT7 might represent a valuable therapeutic option for myeloma, in particular when applied in combination with proteasome inhibitors such as bortezomib. The gene discussed is MAGEC1; the disease is plasma cell myeloma.